PART I Item 1. B usiness Unless the context requires otherwise, the words MannKind, we, Company, us and our refer to MannKind Corporation and its subsidiaries. We are a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart fail...
Q2 FY2026 — expected 2026-08-15
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001193125-26-073516 | EDGAR | 98K words |
| 2025-02-26 | 2024-12-31 | 0000950170-25-027735 | EDGAR | — |
| 2024-02-27 | 2023-12-31 | 0000950170-24-021423 | EDGAR | — |
| 2023-02-23 | 2022-12-31 | 0001564590-23-002309 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0001564590-22-006702 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001564590-21-008440 | EDGAR | — |
| 2020-02-25 | 2019-12-31 | 0001564590-20-006198 | EDGAR | — |
| 2019-02-26 | 2018-12-31 | 0001564590-19-004263 | EDGAR | — |
| 2018-02-27 | 2017-12-31 | 0001564590-18-003510 | EDGAR | — |
| 2017-03-16 | 2016-12-31 | 0001193125-17-085519 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-05 | 2025-09-30 | 0001193125-25-265813 | EDGAR | 68K words |
| 2025-08-06 | 2025-06-30 | 0000950170-25-103535 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0000950170-25-066429 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123296 | EDGAR | — |
| 2024-08-07 | 2024-06-30 | 0000950170-24-092288 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0000950170-24-055661 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0000950170-23-060253 | EDGAR | — |
| 2023-08-07 | 2023-06-30 | 0000950170-23-039074 | EDGAR | — |
| 2023-05-09 | 2023-03-31 | 0000950170-23-019668 | EDGAR | — |
| 2022-11-08 | 2022-09-30 | 0001564590-22-036933 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0001564590-22-028753 | EDGAR | — |
| 2022-05-05 | 2022-03-31 | 0001564590-22-018245 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-26 | 0001193125-26-073509 | EDGAR | 5K words |
| 2025-11-10 | 0001193125-25-273321 | EDGAR | — |
| 2025-11-05 | 0001193125-25-265810 | EDGAR | — |
| 2025-10-09 | 0001193125-25-236064 | EDGAR | — |
| 2025-08-27 | 0000950170-25-111586 | EDGAR | — |
| 2025-08-25 | 0001193125-25-186994 | EDGAR | — |
| 2025-08-06 | 0000950170-25-103532 | EDGAR | — |
| 2025-05-19 | 0000950170-25-074523 | EDGAR | — |
| 2025-05-15 | 0001193125-25-120797 | EDGAR | — |
| 2025-05-08 | 0000950170-25-066426 | EDGAR | — |
282 total filings indexed. 250 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000899460 |
| Ticker | MNKD |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.mannkindcorp.com |
| Listed | 2004-07-28 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report